<VariationArchive VariationID="1065307" VariationName="NM_000552.5(VWF):c.7618del (p.Val2540fs)" VariationType="Deletion" Accession="VCV001065307" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2021-05-01" MostRecentSubmission="2021-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1053547" VariationID="1065307">
      <GeneList>
        <Gene Symbol="VWF" FullName="von Willebrand factor" GeneID="7450" HGNC_ID="HGNC:12726" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12p13.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="5948877" stop="6124670" display_start="5948877" display_stop="6124670" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="6058039" stop="6233835" display_start="6058039" display_stop="6233835" Strand="-" />
          </Location>
          <OMIM>613160</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000552.5(VWF):c.7618del (p.Val2540fs)</Name>
      <CanonicalSPDI>NC_000012.12:5969321:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12p13.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="5969322" stop="5969322" display_start="5969322" display_stop="5969322" variantLength="1" positionVCF="5969321" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="6078488" stop="6078488" display_start="6078488" display_stop="6078488" variantLength="1" positionVCF="6078487" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>V2540fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.6078489del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.6078489del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.5969323del" Assembly="GRCh38">
            <Expression>NC_000012.12:g.5969323del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009072.2" sequenceAccession="NG_009072" sequenceVersion="2" change="g.160349del">
            <Expression>NG_009072.2:g.160349del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000552.5" sequenceAccession="NM_000552" sequenceVersion="5" change="c.7618del" MANESelect="true">
            <Expression>NM_000552.5:c.7618del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000543.3" sequenceAccession="NP_000543" sequenceVersion="3" change="p.Val2540fs">
            <Expression>NP_000543.3:p.Val2540fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_587" sequenceAccession="LRG_587">
            <Expression>LRG_587:g.160349del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_587t1" sequenceAccession="LRG_587t1">
            <Expression>LRG_587t1:c.7618del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_587p1" sequenceAccession="LRG_587p1" change="p.Val2540fs">
            <Expression>LRG_587p1:p.Val2540fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2136356178" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000552.5(VWF):c.7618del (p.Val2540fs) AND von Willebrand disease type 3" Accession="RCV001787225" Version="9">
        <ClassifiedConditionList TraitSetID="89">
          <ClassifiedCondition DB="MedGen" ID="C1264041">von Willebrand disease type 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2021-04-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-04-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-01" MostRecentSubmission="2021-05-01">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <CitationText>www.varsome.com</CitationText>
        </Citation>
        <ConditionList>
          <TraitSet ID="89" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9627" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">von Willebrand disease type 3</ElementValue>
                <XRef ID="128108002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Willebrand disease, severe form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">V WD3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">VON WILLEBRAND DISEASE, TYPE III</ElementValue>
                <XRef Type="MIM" ID="277480" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Willebrand disease, recessive form</ElementValue>
                <XRef ID="Von+Willebrand+disease%2C+recessive+form/7419" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type 3 Von Willebrand's disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type 3 VWD</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VWD3</ElementValue>
                <XRef Type="MIM" ID="277480" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17025" />
                <XRef ID="17025" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Von Willebrand disease (VWD), a congenital bleeding disorder caused by deficient or defective plasma von Willebrand factor (VWF), may only become apparent on hemostatic challenge, and bleeding history may become more apparent with increasing age. Recent guidelines on VWD have recommended taking a VWF level of 30 or 40 IU/dL as a cutoff for those diagnosed with the disorder. Individuals with VWF levels greater than 30 IU/dL and lower than 50 IU/dL can be described as having a risk factor for bleeding. This change in guidelines significantly alters the proportion of individuals with each disease type. Type 1 VWD (~30% of VWD) typically manifests as mild mucocutaneous bleeding. Type 2 VWD accounts for approximately 60% of VWD. Type 2 subtypes include: Type 2A, which usually manifests as mild-to-moderate mucocutaneous bleeding; Type 2B, which typically manifests as mild-to-moderate mucocutaneous bleeding that can include thrombocytopenia that worsens in certain circumstances; Type 2M, which typically manifests as mild-moderate mucocutaneous bleeding; Type 2N, which can manifest as excessive bleeding with surgery and mimics mild hemophilia A. Type 3 VWD (&lt;10% of VWD) manifests with severe mucocutaneous and musculoskeletal bleeding.</Attribute>
                <XRef ID="NBK7014" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301765</ID>
                <ID Source="BookShelf">NBK7014</ID>
              </Citation>
              <XRef ID="166096" DB="Orphanet" />
              <XRef ID="C1264041" DB="MedGen" />
              <XRef ID="MONDO:0010191" DB="MONDO" />
              <XRef Type="MIM" ID="277480" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3096681" SubmissionDate="2021-04-15" DateLastUpdated="2021-05-01" DateCreated="2021-05-01">
        <ClinVarSubmissionID localKey="NM_000552.3:c.7618delG|OMIM:277480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001572745" DateUpdated="2021-05-01" DateCreated="2021-05-01" Type="SCV" Version="1" SubmitterName="Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico" OrgID="507580" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-04-12">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <CitationText>www.varsome.com</CitationText>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VWF" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000552.3:c.7618delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="277480" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyName>Type 3 Von Willebrand International Registries Inhibitor Prospective Study (3WINTERS-IPS)</StudyName>
        <StudyDescription>The 3WINTERS-IPS aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor concentrates used to treat type 3 VWD patients (ClinicalTrials.gov Identifier: NCT02460458)</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>SUB9482148</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3096681" TraitType="Disease" MappingType="XRef" MappingValue="277480" MappingRef="OMIM">
        <MedGen CUI="C1264041" Name="von Willebrand disease type 3" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

